ABHD3 is a phospholipase that functions as a regulator of phospholipid remodeling, with selective substrate specificity for medium-chain phospholipids. The enzyme exhibits predominant phospholipase A1 activity, preferentially cleaving acyl groups at the sn1 position of myristate (C14)-containing phosphatidylcholines, with minor phospholipase A2 activity at the sn2 position 1. ABHD3 also acts on other medium-chain-containing and oxidatively truncated phospholipids. Mechanistically, ABHD3 belongs to the serine hydrolase family and can be selectively inhibited by borylated compounds, demonstrating its catalytic dependence on serine residues 2. Disease relevance extends to hepatic fibrosis, where a circular RNA derived from ABHD3 (circABHD3) is upregulated and promotes epithelial-mesenchymal transition through m6A-dependent mRNA decay pathways and β-catenin signaling activation 3. Additionally, ABHD3 expression is dysregulated in response to environmental stressors: heat stress commonly upregulates ABHD3 across human and mouse tissues 4, while gestational PM2.5 exposure alters ABHD3 placental expression with sex-dependent effects 5. ABHD3 upregulation in hippocampus correlates with enhanced neurogenesis and memory function through leptin-mediated signaling 6. Clinically, ABHD3 represents a potential therapeutic target for hepatic fibrosis intervention and a biomarker for environmental exposure responses.